Advertisement
The 2015 version of the American Board of Internal Medicine maintenance-of-certification program is expected to generate considerable costs

2015 MOC Program Expected to Cost $5.7 Billion Over 10 Years

0
Time costs account for 90 percent of maintenance of certification costs, estimated at $5.1 billion
The recently developed RAPID score

RAPID Score Validated for Prognosis of Pleural Infections

0
Recently developed score is valid for identifying mortality risk through five years in diverse cohort
For canagliflozin-treated patients with type 2 diabetes

Low Incidence of Diabetic Ketoacidosis With Canagliflozin

0
Canagliflozin-treated patients with type 2 diabetes have low incidence of serious adverse DKA events
The ReShape Integrated Dual Balloon System has been approved by the U.S. Food and Drug Administration to combat adult obesity. Inflated inside the stomach

FDA Approves Balloon Device to Treat Obesity

0
Inflated in stomach, it may create sense of fullness
From 2002 to 2012

Higher Health Costs for Diabetes Mainly Meds, Inpatient Care

0
Individuals with diabetes had more than double the unadjusted mean direct expenditures over 10 years
For Japanese patients who have undergone percutaneous coronary intervention

Atorvastatin/Ezetimibe Beats Atorvastatin After PCI

0
Combination therapy linked to greater coronary plaque regression in Japanese patients
Components of the Mediterranean lifestyle may reduce postprandial lipemia

Components of Mediterranean Lifestyle Cut Postprandial Lipemia

0
Physical activity shown to reduce PPL, as well as legumes, fish, and herbs, but not wine
Millions more Americans have affordable health insurance

Patients Report Improved Care Access, Better Health With ACA

0
Gains seen in how many adults have insurance and a doctor, and say they are in better health
Patients with diabetes and a lower extremity amputation are more likely to die

Risk of Death Up With Lower Extremity Amputation in Diabetes

0
Some, but not all, of the increased risk attributed to diabetes-related complications
Praluent (alirocumab) injection has been approved by the U.S. Food and Drug Administration for use in addition to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease

FDA Approves Praluent for Certain Cases of High Cholesterol

0
First in a new class of injectable cholesterol-lowering medications